Literature DB >> 21183936

High leptin/adiponectin ratio and serum triglycerides are associated with an "at-risk" phenotype in young severely obese patients.

Giuseppe Labruna1, Fabrizio Pasanisi, Carmela Nardelli, Rosanna Caso, Dino F Vitale, Franco Contaldo, Lucia Sacchetti.   

Abstract

"At-risk" severely obese subjects are characterized by insulin resistance, and higher visceral fat and plasma lipid levels compared with metabolically healthy obese (MHO) subjects, although both groups have a high BMI and fat mass. The aim of this study was to measure several serum adipokines and gastrointestinal hormones in a young severely obese population from Southern Italy to identify biochemical markers of the "at-risk" insulin-resistant obese profile. We studied 160 unrelated white young adults (mean age = 25.2 years, mean BMI = 44.9 kg/m(2), 65% women) affected by obesity for at least 5 years. Serum concentrations of glucagon, ghrelin, gastric inhibitory peptide, glucagon like peptide-1, interleukin-6, tumor necrosis factor α, leptin, adiponectin, adipsin, and visfatin were measured. The leptin/adiponectin (L/A) ratio and fatty liver index (FLI) were calculated. We found a prevalence of 21.3% of MHO patients in our young severely obese patients. At univariate analysis, the "at-risk" group had higher mean levels of BMI (P < 0.0001), leptin (P = 0.039, men) and the L/A ratio (P = 0.003), and lower mean levels of visfatin (P = 0.026) than the MHO group. The L/A ratio, serum triglycerides, and male sex were significantly associated with "at-risk" obesity and accounted for 19.5% of insulin resistance at multivariate analysis. In conclusion, we demonstrate that a high serum L/A ratio and high levels of serum triglycerides may be markers of "at-risk" obesity, independent of waist circumference (WC) and BMI, in young severely obese population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21183936     DOI: 10.1038/oby.2010.309

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  28 in total

1.  The adipokine profile of metabolically benign obese and at-risk normal weight postmenopausal women: the Women's Health Initiative Observational Study.

Authors:  Unab I Khan; Alexandra D Ogorodnikova; Linzhi Xu; Dan Wang; Sylvia Wassertheil-Smoller; Gloria Y F Ho; Mary Fran R Sowers; Swapnil N Rajpathak; Matthew A Allison; Rachel H Mackey; Mara Z Vitolins; Joann E Manson; Rachel P Wildman
Journal:  Obesity (Silver Spring)       Date:  2013-12-20       Impact factor: 5.002

2.  Ovarian adipocytokines are associated with early in vitro human embryo development independent of the action of ovarian insulin.

Authors:  Liyun Li; Michel Ferin; Mark V Sauer; Roger A Lobo
Journal:  J Assist Reprod Genet       Date:  2012-10-04       Impact factor: 3.412

3.  Roux-en-Y gastric bypass decreases pro-inflammatory and thrombotic biomarkers in individuals with extreme obesity.

Authors:  Bárbara Dal Molin Netto; Solange Cravo Bettini; Ana Paula Grotti Clemente; Joana Pereira de Carvalho Ferreira; Katia Boritza; Sandy de Fátima Souza; Maria Emilia Von der Heyde; Carrie P Earthman; Ana R Dâmaso
Journal:  Obes Surg       Date:  2015-06       Impact factor: 4.129

4.  The absence of polymorphisms in ADRB3, UCP1, PPARγ, and ADIPOQ genes protects morbid obese patients toward insulin resistance.

Authors:  R Bracale; G Labruna; C Finelli; A Daniele; L Sacchetti; G Oriani; F Contaldo; F Pasanisi
Journal:  J Endocrinol Invest       Date:  2012-01       Impact factor: 4.256

5.  Laparoscopic adjustable gastric banding reduces subcutaneous adipose tissue and blood inflammation in nondiabetic morbidly obese individuals.

Authors:  Laura Iaffaldano; Carmela Nardelli; Vincenzo Pilone; Giuseppe Labruna; Andreina Alfieri; Donatella Montanaro; Maddalena Ferrigno; Maria Restituta Zeccolella; Nicola Carlomagno; Andrea Renda; Alfonso Baldi; Pietro Forestieri; Lucia Sacchetti; Pasqualina Buono
Journal:  Obes Surg       Date:  2014-12       Impact factor: 4.129

6.  High aminopeptidase N/CD13 levels characterize human amniotic mesenchymal stem cells and drive their increased adipogenic potential in obese women.

Authors:  Laura Iaffaldano; Carmela Nardelli; Maddalena Raia; Elisabetta Mariotti; Maddalena Ferrigno; Filomena Quaglia; Giuseppe Labruna; Valentina Capobianco; Angela Capone; Giuseppe Maria Maruotti; Lucio Pastore; Rosa Di Noto; Pasquale Martinelli; Lucia Sacchetti; Luigi Del Vecchio
Journal:  Stem Cells Dev       Date:  2013-04-23       Impact factor: 3.272

7.  Ectopic fat and adipokines in metabolically benign overweight/obese women: the Kronos Early Estrogen Prevention Study.

Authors:  Alexandra D Ogorodnikova; Unab I Khan; Aileen P McGinn; Irfan Zeb; Matthew J Budoff; S M Harman; Virginia M Miller; Eliot A Brinton; JoAnn E Manson; Howard N Hodis; George R Merriam; Marcelle I Cedars; Hugh S Taylor; Frederick Naftolin; Rogerio A Lobo; Nanette Santoro; Rachel P Wildman
Journal:  Obesity (Silver Spring)       Date:  2013-05-13       Impact factor: 5.002

8.  A stable isotope biomarker of marine food intake captures associations between n-3 fatty acid intake and chronic disease risk in a Yup'ik study population, and detects new associations with blood pressure and adiponectin.

Authors:  Diane M O'Brien; Alan R Kristal; Sarah H Nash; Scarlett E Hopkins; Bret R Luick; Kimber L Stanhope; Peter J Havel; Bert B Boyer
Journal:  J Nutr       Date:  2014-03-05       Impact factor: 4.798

9.  Cytosolic malic enzyme 1 (ME1) mediates high fat diet-induced adiposity, endocrine profile, and gastrointestinal tract proliferation-associated biomarkers in male mice.

Authors:  Ahmed Al-Dwairi; John Mark P Pabona; Rosalia C M Simmen; Frank A Simmen
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

10.  Prevalence of metabolic syndrome in a cohort of Chinese schoolchildren: comparison of two definitions and assessment of adipokines as components by factor analysis.

Authors:  Qiaoxuan Wang; Jinhua Yin; Lu Xu; Hong Cheng; Xiaoyuan Zhao; Hongding Xiang; Hugh Simon Lam; Jie Mi; Ming Li
Journal:  BMC Public Health       Date:  2013-03-21       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.